Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from BioAtla ( (BCAB) ).
On January 9, 2026, BioAtla’s board authorized the issuance of a single Series A Junior Preferred “Super-Voting” share to Chairman and CEO Jay M. Short for $0.01, granting him voting power equal to all common shares outstanding, but only on proposals related to a potential reverse stock split, related adjournments, or other board-designated, closely related matters. The special preferred share, which carries no dividend rights, minimal liquidation preference, strict transfer restrictions, and is redeemable by the board for $0.01, was created after stockholders on December 30, 2025 failed to deliver the required two-thirds voting power to approve a reverse stock split, despite majority support, and the special meeting was adjourned and reconvened on January 12, 2026, then again to January 26, 2026, with the new share designed to ensure that if at least two-thirds of the common stock voting at the reconvened meeting supports the reverse stock split, the company can secure formal approval and continue efforts to maintain compliance with Nasdaq listing standards.
The most recent analyst rating on (BCAB) stock is a Hold with a $0.43 price target. To see the full list of analyst forecasts on BioAtla stock, see the BCAB Stock Forecast page.
Spark’s Take on BCAB Stock
According to Spark, TipRanks’ AI Analyst, BCAB is a Neutral.
The score is held down primarily by very weak financial performance (no TTM revenue, large losses, ongoing cash burn, and negative equity) and bearish technicals (price well below major moving averages with negative MACD). Offsetting support comes from constructive program/regulatory updates on the earnings call and a financing-related corporate event that improves funding outlook for the Phase 3 program, while valuation signals are limited due to negative earnings and no dividend.
To see Spark’s full report on BCAB stock, click here.
More about BioAtla
BioAtla, Inc. is a Delaware-incorporated public company listed on Nasdaq that issues common stock and uses equity financing tools such as pre-paid advance agreements and standby equity purchase agreements to fund its operations, with shareholders recently asked to approve a potential reverse stock split to help manage its capital structure and listing requirements.
Average Trading Volume: 1,705,666
Technical Sentiment Signal: Sell
Current Market Cap: $23.65M
Learn more about BCAB stock on TipRanks’ Stock Analysis page.